Maria E Nizzoli,et al. Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.Hematol Oncol . 2023 M...
Beyond R-CHOP for LymphomaAlice Goodman
弥漫大B细胞淋巴瘤(DLBCL)是最常见的一类淋巴瘤,中国每年新发病例约3万人,国内外临床诊疗指南和共识均推荐R-CHOP方案作为DLBCL的标准一线治疗方案,但在总体人群中仍有约1/3或以上的患者对一线R-CHOP治疗无效或早期复发。同时,在DLBCL中约有30%患者存在着MYC/BCL2蛋白同时过度表达(简称"双表达"淋巴瘤,DEL),其经...
1.Annalisa Arcari, Lugi Rigacci, Alessandra Tucci, et al. A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma. Blood Adv. 2023 Aug 8;7(15):4160-4169. doi...
2024年4月24日,上海交通大学医学院附属瑞金医院赵维莅教授团队《Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study》入选美国临床肿瘤学会(American Society of Clinical Oncology,简称ASCO...
展开 关键词: follicular lymphoma histological transformation long term R-CHOP secondary malignancies NON-HODGKINS-LYMPHOMA LOW-GRADE LYMPHOMA ADVANCED-STAGE RITUXIMAB MAINTENANCE HISTOLOGICAL TRANSFORMATION RETROSPECTIVE ANALYSIS MULTIVARIATE-ANALYSIS PROGNOSTIC-FACTORS INITIAL TREATMENT RISK-FACTORS DOI...
1、RFND方案与RCHOP方案治疗MALT淋巴瘤的效果比较黏膜相关淋巴组织边缘区B细胞淋巴瘤(MALT lymphoma)现仍无标准化疗方案,既往临床多以CHOP、CVP方案等为主。近年来,以氟达拉滨为代表的新嘌呤类似物在MALT淋巴瘤中的治疗价值得到明确肯定,氟达拉滨联合烷化剂方案(氟达拉滨+米托蒽醌+地塞米松,FND)在临床治疗中得到...
弥漫大B细胞淋巴瘤(Diffuse Large B-Cell Lymphoma, DLBCL)是临床最常见的非霍奇金淋巴瘤,60%左右的患者一线免疫化疗(如R-CHOP方案)后都可获得完全缓解和长期无病生存。多年来,R-CHOP一直是DLBCL的标准一线治疗,药物组成包括利妥昔单抗(Rituximab)、环磷酰胺(Cyclophosphamide)、多柔比星(Doxorubicin)、长春新碱(Vin...
FDA批准Polivy联合R-CHP用于DLBCL的一线治疗是基于POLARIX的关键数据,POLARIX是一项国际III期随机双盲安慰剂对照研究,证明与R-CHOP相比,PFS有统计学意义和临床意义的改善。与R-CHOP相比,Polivy加R-CHP (n=440)的疾病进展、复发或死亡风险降低了27 %。 至于安全性,报告的最常见不良事件包括周围神经病变、恶心、疲劳、...
DEL patients undergoing first-line treatment with R-CHOP regimen have poor prognosis. 【Key words】 Diffuse with large B-cell lymphoma Clinical features Effectiveness Double expression 弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)是非霍奇金淋巴瘤最常见的 亚型,约占所有非霍奇金淋巴瘤病例的...